Disease-modifying treatments for progressive multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 11, 2013, Pages 1428-1436

  Comi, Giancarlo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

disease modifying therapies; Multiple sclerosis; progressive multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; DIRUCOTIDE; DRONABINOL; ERYTHROPOIETIN; FUMARIC ACID; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; LAMOTRIGINE; LAQUINIMOD; METHOTREXATE; MINOCYCLINE; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; PLACEBO; RILUZOLE; RITUXIMAB; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; BRAIN ATROPHY; BRAIN SIZE; CLINICAL TRIAL (TOPIC); DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROCYTE PRECURSOR CELL; PHASE 3 CLINICAL TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; REMYELINIZATION; REVIEW; SPASTICITY; SPINAL CORD ATROPHY;

DISEASE-MODIFYING THERAPIES; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIPLE SCLEROSIS;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEUROPROTECTIVE AGENTS;

EID: 84884543234     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513502572     Document Type: Review

References (106)

1. Paty DW, Li DK. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993 ; 43: 662-667
2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993 ; 43: 655-661
3. Gold R, Montalban X. Multiple sclerosis: More pieces of the immunological puzzle. Lancet Neurol. 2012 ; 11: 9-10
4. Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol. 2013 ;:
5. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: Treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011 ; 17: 970-979
6. Zipoli V, Portaccio E, Hakiki B, et al. Intravenous mitoxantrone and cyclophosphamide as a second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. J Neurol Sci. 2008 ; 266: 25-30
7. Comi G. Clinically isolated syndrome: The rationale for early treatment. Nat Clin Pract Neurol. 2008 ; 4: 234-235
8. Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2012 ;:
9. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet. 2009 ; 374: 1503-1511
10. Comi G, Filippi M, Barkhof F, et al. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet. 2001 ; 357: 1576-1582
11. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998 ; 352: 1491-1497
12. Krapf H, Morrissey SP, Zenker O, et al. Effect of mitoxantrone on MRI in progressive MS: Results of the MIMS trial. Neurology. 2005 ; 65: 690-695
13. Martinelli-Boneschi F, Esposito F, Scalabrini D, et al. Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. Eur J Neurol. 2010 ; 17: 740-745
14. Howell OW, Palser A, Polito A, et al. Disruption of neurofascin localization reveals early change preceding demyelination and remyelination in multiple sclerosis. Brain. 2006 ; 129: 3173-3185
15. Meinl E, Krumbholz M, Derfuss T, et al. Compartmentalization of inflammation in the CNS: A major mechanism driving progressive multiple sclerosis. J Neurol Sci. 2008 ; 274: 42-44
16. Filippi M, Rovaris M, Rocca MA. Imaging primary progressive multiple sclerosis: The contribution of structural, metabolic, and functional MRI techniques. Mult Scler. 2004 ; 10: S36 - S44
17. Agosta F, Absinta M, Sormani MP, et al. In vivo assessment of cervical cord damage in MS patients: A longitudinal diffusion tensor MRI study. Brain. 2007 ; 130: 2211-2219
18. Rovaris M, Judica E, Sastre-Garriga J, et al. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Mult Scler. 2008 ; 14: 455-464
19. Sepulcre J, Masdeu JC, Goni J, et al. Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler. 2009 ; 15: 337-344
20. Kolasinski J, Stagg CJ, Chance SA, et al. A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain. 2012 ; 135: 2938-2951
21. Fisher E, Lee JC, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol. 2008 ; 64: 255-265
22. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008 ; 64: 247-254
23. Calabrese P, Penner IK. Cognitive dysfunctions in multiple sclerosis - a 'multiple disconnection syndrome'?. J Neurol. 2007 ; 254: S18 - S21
24. Calabrese M, Rinaldi F, Mattisi I, et al. Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology. 2010 ; 74: 321-328
25. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005 ; 128: 2705-2712
26. Kutzelnigg A, Faber-Rod JC, Bauer J, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007 ; 17: 38-44
27. Geurts JJ, Bo L, Roosendaal SD, et al. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol. 2007 ; 66: 819-827
28. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011 ; 134: 2755-2771
29. Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012 ; 135: 2925-2937
30. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007 ; 130: 1089-1104
31. Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010 ; 68: 477-493
32. Luchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011 ; 365: 2188-2197
33. Chang A, Staugaitis SM, Dutta R, et al. Cortical remyelination: A new target for repair therapies in multiple sclerosis. Ann Neurol. 2012 ; 72: 918-926
34. Waxman SG. Axonal dysfunction in chronic multiple sclerosis: Meltdown in the membrane. Ann Neurol. 2008 ; 63: 411-413
35. Dutta R, McDounough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006 ; 59: 478-489
36. Orbach R, Zhao Z, Wang YC, et al. Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS One. 2012 ; 7: e45409
37. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: Pathology and pathogenesis. Nat Rev Neurol. 2012 ; 8: 647-656
38. Bramow S, Frischer JM, Lassmann H, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010 ; 133: 2983-2998
39. Kappos L, Weinshenker B, Pozzilli C, et al. European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board. Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials. Neurology. 2004 ; 23 63: 1779-1787
40. Hartung HP, Gonsette R, König N, et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised multicentre trial. Lancet. 2002 ; 360: 2018-2025
41. Goodin DS, Traboulsee A, Knappertz V, et al. 16-year long term follow-up study investigators. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 ; 83: 282-287
42. Randomized controlled trial of interferon beta-1a in secondary progressive MS: Clinical results. Neurology. 2001 ; 56: 1496-1504
43. Andersen O, Elovaara I, Färkkilä M, et al. Multicentre, randomised, double-blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004 ; 75: 706-710
44. Cohen JA, Cutter GR, Fischer JS, et al. IMPACT investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002 ; 59: 679-687
45. La Mantia L, Vacchi L, Di Pietrantonj C, et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev. 2012 ; 1 :
46. Fidler JM, DeJoy SQ, Gibbons JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol. 1986 ; 137: 727-732
47. Morissey SP, Le Page E, Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int MS J. 2005 ; 12: 74-87
48. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: Safety considerations. Neurology. 2004 ; 63: S28 - S32
49. Martinelli V, Cocco E, Capra R, et al. Italian Mitoxantrone Group. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 2011 ; 77: 1887-1995
50. Esposito F, Radaelli M, Martinelli V, et al. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2010 ; 16: 1490-1499
51. Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology. 1991 ; 41: 533-539
52. Fazekas F, Sorensen PS, Filippi M, et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler. 2005 ; 11: 433-440
53. Pohlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: A randomized placebo controlled multicentre study. Mult Scler. 2007 ; 13: 1107-1117
54. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995 ; 37: 30-40
55. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose oral methotrexate in chronic progressive multiple sclerosis: Analyses of serial MRIs. Neurology. 1996 ; 47: 1153-1157
56. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple. Lancet. 1991 ; 337: 441-446
57. Weiner HL, Mackin GA, Oray EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993 ; 43: 910-918
58. Zephir H, de Seze J, Duhamel A, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: A cohort study of 490 patients. J Neurol Sci. 2004 ; 218: 73-77
59. Giovannoni G, Comi G, Cook S, et al. CLARITY Study Group. A placebo-controlled trial of oral Cladribine for relapsing-remitting multiple sclerosis. N Engl J Med. 2010 ; 362: 416-426
60. Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994 ; 344: 9-13
61. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000 ; 54: 1145-1155
62. Filippi M, Rovaris M, Iannucci G, et al. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology. 2000 ; 55: 1714-1718
63. Ratzinger G, Reagan JL, Heller G, et al. Differential CD52 expression by distinct myeloid dendritic cell subsets: Implications for alemtuzumab activity at the level of antigen presentation in allogenic graft-host interactions in transplantation. Blood. 2003 ; 101: 1422-1429
64. Coles AJ, Twyman CL, Arnold DL, et al. CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet. 2012 ; 380: 1829-1839
65. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012 ; 78: 1069-1078
66. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology. 1999 ; 53: 751-757
67. Reston JT, Uhl S, Treadwell JR, et al. Autologous hematopoietic cell transplantation for multiple sclerosis: A systematic review. Mult Scler. 2011 ; 17: 204-213
68. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 2008 ; 7: 626-636
69. Bowen JD, Kraft GH, Wundes A, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: Long term results. Bone Marrow Transplant. 2012 ; 47: 946-951
70. Fassas A, Kimiskidis VK, Sakellari I, et al. Long-term results of stem cell transplantation for MS: A single-center experience. Neurology. 2011 ; 76: 1066-1070
71. Holmony T. Immunopathogenesis of multiple sclerosis: Concepts and controversies. Acta Neurol Scand Suppl. 2007 ; 187: 39-45
72. Freedman MS, Bar-Or A, Oger J, et al. MAESTRO-01 Investigators. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011 ; 77: 1551-1560
73. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: An exploratory, randomized, controlled trial. Neurology. 2003 ; 60: 44-51
74. Montalban X, Sastre-Garriga J, Tintoré M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009 ; 15: 1195-1205
75. Wolinsky JS, Narayana PA, O'Connor P, et al. PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007 ; 61: 14-24
76. Wolinsky JS, Shochat T, Weiss S, et al. PROMiSe Trial Study Group. Glatiramer acetate treatment in PPMS; why males appear to respond favourably. J Neurol Sci. 2009 ; 286: 92-98
77. Hawker K, O'Connor P, Freedman MS, et al. OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 ; 66: 460-471
78. Hauser SL, Waubant E, Arnold DL, et al. HERMES Trial Group. B-Cell depletion with rituximab in relapsing-remitting multiple sclerosis. New Engl J Med. 2008 ; 358: 676-688
79. Konishi Y, Chui DH, Hirose H, et al. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 1993 ; 609: 29-35
80. Campana WM, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: Changes after nerve injury. Faseb J. 2001 ; 15: 1804-1806
81. Zhang J, Li Y, Cui Y, et al. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. 2005 ; 1034: 34-39
82. Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007 ; 130: 2577-2588
83. Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: A pilot study. Mult Scler. 2002 ; 8: 532-533
84. Kapoor R, Davies M, Blaker PA, et al. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol. 2003 ; 53: 174-180
85. Bechtold DA, Kappor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol. 2004 ; 55: 607-616
86. Bechtold DA, Yue X, Evans RM, et al. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent fleacainide. Brain. 2005 ; 128: 18-28
87. Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010 ; 9: 681-688
88. Chataway, et al. The MS-STAT trial: High dose simvastatin demonstrates neuroprotection without immune-modulation in secondary progressive multiple sclerosis (SPMS) - a phase II trial. ECTRIMS 2012 ; ;..
89. Giuliani F, F SA, Metz LM, et al. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol. 2005 ; 165: 83-91
90. Haaseldam H, Johansen FF. Cannabinoid treatment renders neurons less vulnerable than oligodendrocytes in experimental autoimmune encephalomyelitis. Int J Neurosci. 2011 ; 121: 510-520
91. Chung YC, Bok E, Huh SH, et al. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol. 2011 ; 187: 6508-6517
92. Rossi S, Buttari F, Studer V, et al. The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing-remitting multiple sclerosis. Mult Scler. 2011 ; 17: 281-288
93. Zajicek J, Ball S, Wright D, et al. on behalf of CUPID investigator group. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): A randomised, placebo-controlled trial. Lancet Neurology. 2013 ;:
94. Martino G, Franklin RJ, Baron Van Evercooren A, et al. Stem Cells in Multiple Sclerosis (STEMS) Consensus Group. Stem cell transplantation in multiple sclerosis: Current status and future prospects. Nat Rev Neurol. 2010 ; 6: 247-255
95. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: A new strategy for immunosuppression?. Trends Immunol. 2007 ; 28: 219-226
96. Freedman MS, Bar-Or A, Atkins HL, et al. MSCT Study Group. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the international MSCT Study Group. Mult Scler. 2010 ; 16: 503-510
97. Connik P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol. 2012 ; 11: 150-156
98. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010 ; 67: 1187-1194
99. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of pilot study. Iran J Immunol. 2007 ; 4: 50-57
100. Yamouth B, Hourani R, Salti H, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. Neuroimmunol. 2010 ; 227: 185-189
101. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cell as treatment for MS - progress to date. Mult Scler. 2013 ; 19: 515-519
102. Hanafy KA, Sloane JA. Regulation of remyelination in multiple sclerosis. FEBS Lett. 2011 ; 585: 3821-3828
103. Sabo JK, Cate HS. Signalling pathways that inhibit the capacity of precursor cells for myelin repair. Int J Mol Sci. 2013 ; 14: 1031-1049
104. Han MH, Hwang S, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008 ; 451: 1076-1081
105. Rudick RA, Mi S, Sandrock AW. LINGO-1 antagonists as therapy for multiple sclerosis: In vitro and in vivo evidence. Expert Opin Biol Ther. 2008 ; 8: 1561-1570
106. Mi S, Blake Pepinski R, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: From concept to the clinic. CNS Drugs. 2013 ; 27: 493-503